

CITATION REPORT

List of articles citing

Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis

DOI: 10.1016/j.jval.2014.10.013
Value in Health, 2015, 18, 173-9.

Source: <https://exaly.com/paper-pdf/62285092/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
24	Tocilizumab monotherapy worth its cost in severe active RA. <i>PharmacoEconomics & Outcomes News</i> , 2015 , 724, 26-26	0.1	
23	Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. <i>Rheumatology International</i> , 2015 , 35, 1489-95	3.6	7
22	Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate. <i>Advances in Therapy</i> , 2016 , 33, 1360-73	4.1	7
21	Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. <i>Clinical Therapeutics</i> , 2016 , 38, 1359-1375.e1	3.5	10
20	Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. <i>Journal of Medical Economics</i> , 2017 , 20, 703-714	2.4	11
19	Modelling the cost-effectiveness of statin therapy in rheumatoid arthritis: a Markov-cycle evaluation from national data bank for rheumatic diseases. <i>Journal of Pharmaceutical Health Services Research</i> , 2017 , 8, 139-145	1	
18	An Introduction to Economic Evaluation of Health Care Programs. 2017 , 1-9		
17	Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis. <i>Journal of Medical Economics</i> , 2018 , 21, 712-720	2.4	3
16	Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2019 , 11, 395-403	1.7	5
15	A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2019 , 37, 829-843	4.4	15
14	Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 80-87	1.9	6
13	Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020 , 7, 165-171	4.4	2
12	Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 775-784	2.2	1
11	The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 1236-1242	1.9	2
10	Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China. <i>Pharmacoeconomics</i> , 2020 , 38, 1345-1358	4.4	7
9	A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020 , 20, 221-228	2.2	1
8	Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. <i>Rheumatology and Therapy</i> , 2020 , 7, 517-535	4.4	6

7	Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs. <i>Pharmacoeconomics</i> , 2020 , 38, 459-471	4.4	7
6	Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review. <i>Journal of Medical Economics</i> , 2020 , 23, 610-623	2.4	
5	Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure. <i>Rheumatology and Therapy</i> , 2021 , 8, 775-791	4.4	1
4	Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China. <i>Rheumatology and Therapy</i> , 2021 , 8, 863-876	4.4	0
3	Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population. <i>Advances in Therapy</i> , 2021 , 38, 2571-2585	4.1	2
2	Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	0
1	Cost-Effectiveness Analyses of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Diseases in Patients With Rheumatoid Arthritis: Three Approaches with a Cohort Simulation and Real-World Data.. <i>Modern Rheumatology</i> , 2022 ,	3.3	0